Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus — RATE  

Barrett Esophagus Clinical Trial

Official title: Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus - the Patients' Perspective: a Randomized Controlled Trial Assessing Procedural Acceptability and Safety (RATE Study)

Status Recruiting

Clinical Trial Summary

This study compares patients' acceptability and safety of two established endoscopic methods for treating dysplastic Barrett's esophagus: radiofrequency ablation versus hybrid argon plasma coagulation.

Clinical Trial Description

Both endoscopic radiofrequency ablation (RFA) and argon plasma coagulation (APC) are established treatment modalities for dysplastic Barrett's esophagus. Recently, a modification of the APC method has emerged, which involves a submucosal injection of saline preceding the thermal ablation (hybrid-APC; h-APC). This allows to increase the procedure's safety and presumably reduces the patients' post-procedural discomfort. Although both RFA and h-APC are characterized by high effectiveness in eradicating Barrett's segments, limited data compares the patient-related aspects of the procedures. To fill this knowledge gap, we set out a single-center randomized-controlled trial to compare procedural acceptability, safety, and impact on the quality of life, of the two methods. ;

Related Conditions & MeSH terms

• Barrett Esophagus
• Esophageal Adenocarcinoma
• Reflux Disease

• NCT number: NCT05051475
• Study type: Interventional
• Source: Centre of Postgraduate Medical Education
• Contact: Wladyslaw Jannuszewicz, MD
• Phone: +48 546-23-28
• Email: wjanuszewicz@cmkp.edu.pl
• Status: Recruiting
• Phase: N/A
• Start date: December 1, 2021
• Completion date: December 31, 2023